Genzyme Next-Generation Osteoarthritis Candidate Hylastan Found Not Superior To Steroids
This article was originally published in The Pink Sheet Daily
Executive Summary
Failed therapy is now on the back burner, as focus turns to approval and introduction of single-treatment viscosupplementation product Synvisc-One, company tells “The Pink Sheet” DAILY.
You may also be interested in...
Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.
Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies
“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.
Bioenvision Investors Unhappy With Genzyme Acquisition Deal
Web site urges shareholders to reject Genzyme’s “lowball” tender offer.